Segment Information (Tables)

6 Months Ended

Jun. 30, 2013

Revenues, Cost Of Services And Products, And Gross Margins For Operating Segments


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Revenues:
Medical devices	$	18,195	$	16,696	$	37,991	$	33,150
Preservation services		15,317		16,313		30,994		31,972
Other^a		8		179		71		367
Total revenues		33,520		33,188		69,056		65,489

Cost of products and preservation services:
Medical devices		3,721		2,673		7,186		5,186
Preservation services		8,320		9,144		17,115		17,640
Total cost of products and preservation services		12,041		11,817		24,301		22,826

Gross margin:
Medical devices		14,474		14,023		30,805		27,964
Preservation services		6,997		7,169		13,879		14,332
Other^a		8		179		71		367
Total gross margin	$	21,479	$	21,371	$	44,755	$	42,663

Summary Of Net Revenues By Product


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2013		2012		2013		2012
Products:
BioGlue and BioFoam	$	13,542	$	13,437	$	29,006	$	27,133
PerClot		940		691		1,804		1,335
Revascularization technologies		2,293		1,933		4,484		4,047
HeRO Graft		1,420		635		2,697		635
Total products		18,195		16,696		37,991		33,150

Preservation services:
Cardiac tissue		6,818		7,343		13,463		14,423
Vascular tissue		8,499		8,970		17,531		17,549
Total preservation services		15,317		16,313		30,994		31,972

Other^a		8		179		71		367
Total revenues	$	33,520	$	33,188	$	69,056	$	65,489

___________________

^a For the three and six months ended June 30, 2013 and 2012 the “Other” designation includes grant revenue.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details